BMS Makes Deeper Dent In Asia Hepatitis Market As Baraclude Moves Toward Blockbuster Status
This article was originally published in PharmAsia News
BMS’ hepatitis B therapy Baraclude moves toward blockbuster status as company highlights risk of drug resistance with older treatments.
You may also be interested in...
Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources